Targeted delivery of 5-fluorouracil with monoclonal antibody modified bovine serum albumin nanoparticles

Iranian Journal of Pharmaceutical Research

Volumn 14, Issue 2, 2015, Pages 395-405

  Fadaeian, Ghazal ^a   Shojaosadati, Seyed Abbas ^a   Kouchakzadeh, Hasan ^a   Shokri, Fazel ^b,c   Soleimani, Masoud ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

1F2 monoclonal antibody; 5 Flourouracil; Bovine serum albumin nanoparticles

Indexed keywords

ANTI HER2 MONOCLONAL ANTIBODY; BOVINE SERUM ALBUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; MACROGOL; MONOCLONAL ANTIBODY; NANOPARTICLE; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ARTICLE; CELL VIABILITY; CHEMICAL BINDING; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG CONJUGATION; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MTT ASSAY; PARTICLE SIZE; POLYDISPERSITY INDEX; THIOLATION; ZETA POTENTIAL;

EID: 84922982978     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Longley DB, Harkin DP and Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer (2003) 3: 330-338.
2. Pinedo HM and Peters GF. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. (1998) 6: 1653-1664.
3. Alter P, Herzum M, Souf M, Schaefer JR and Maisch B. Cardiotoxicity of 5- fuorouracil. cardiovasc, cardiovasc. Hematol. Agents Med. Chem. (2006) 4: 1-5.
4. Wigmore PM, Mustafa S, El-Beltagy M, Lyons L, Umka J and Bennett G. Effects of 5-FU. Adv. Exp. Med. Biol. (2010) 678: 157-164.
5. Noori Koopaei M, Khoshayand MR, Mostafavi SH, Amini M, Khorramizadeh MR, Jeddi Tehrani M, Atyabi F and Dinarvand R. Docetaxel loaded PEG-PLGA nanoparticles: optimized drug loading, in-vitro cytotoxicity and in-vivo antitumor effect. Iran. J. Pharm. Res. (2014) 13: 819-833.
6. Kouchakzadeh H, Shojaosadati SA, Mohammadnejad J, Paknejad M and Rasaee MJ. Attachment of an anti-MUC1 monoclonal antibody to 5-FU loaded BSA nanoparticles for active targeting of breast cancer cells. Hum. Antibodies (2012) 21: 49-56.
7. Danhier F, Feron O and Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, J. Control. Release (2010) 148: 135-146.
8. Li XM, Ding LY, Xu Y, Wang Y and Ping QN. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int. J. Pharm. (2009) 373: 116-123.
9. Xu S, Olenyuk BZ, Okamoto CT and Hamm-Alvarez SF. Targeting receotor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv. Drug Deliv. Rev. (2013) 65: 121-138.
10. Elzoghby AO, Samy WM and Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control. Release (2012) 157: 168-182.
11. Bansal A, Kapoor DN, Kapil R, Chhabra N and Dhawan S. Design and development of paclitaxelloaded bovine serum albumin nanoparticles for brain targeting. Acta Pharm. (2011) 61: 141-156.
12. Wacker M, Zensi A, Kufeitner J, Ruff A, Schutz J and Vogel V. A toolbax for the upscaling of ethanolic human serum albumin (HSA) desolvation. Int. J. Pharm. (2011) 414: 225-232.
13. Elsadek B and Kratz F. Impact of albumin on drug delivery-new applications on the horizon. J. Control. Release (2012) 157: 4-28.
14. Tai W, Mahato R and Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J. Control. Release (2010) 146: 264-275.
15. Alirezapour B, Jalilian A, Bolourinovin F and Moradkhani S. Production and quality control of [67Ga]-DOTA-trastuzumab for radioimmunoscintigraphy. Iran. J. Pharm. Res. (2013) 12: 355-366.
16. Kazemi T, Tahmasebi F, Bayat A, Mohajer N, Khoshnoodi J, Jeddi-Tehrani M, Rabbani H and Shokri F. Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor. Hybridoma (2011) 30: 347-353.
17. Kouchakzadeh H, Shojaosadati SA, Tahmasebi F and Shokri F. Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles. Int. J. Pharm. (2013) 447: 62-69.
18. Maghsoudi A, Shojaosadati SA and Vasheghani Farahani E. 5-Fluorouracil-loaded BSA nanoparticles: formulation optimization and in-vitro release study. AAPS Pharm. Sci. Tech. (2008) 9: 1092-1096.
19. Kouchakzadeh H, Shojaosadati SA, Maghsoudi A and Vasheghani Farahani E. Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology. AAPS Pharm. Sci. Tech. (2010) 11: 1206-1211.
20. Langer K, Balthasar S, Vogel V, Dinauer N, Briesen HV and Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int. J. Pharm. (2003) 257: 169-180.
21. Anhorn MG, Mahler HC and Langer K. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients. Int. J. Pharm. (2008) 363: 162-169.
22. Hosono Y, Osada S, Nawa M, Takahashi T, Yamaguchi K, Kawaguchi Y and Yoshida K. Combination therapy of 5-fluorouracil with rapamycin for hormone receptor-negative human breast cancer. Anticancer Res. (2010) 30: 2625-2630.
23. Anhorn MG, Wagner S, Kreuter J, Langer K and von Briesen H. Specific targeting of Her2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modifed human serum albumin nanoparticles. Bioconjugate Chem. (2008) 19: 2321-2331.
24. Steinhauser I, Spankuch B, Strebhardtb K and Langer K. Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells. Biomaterials (2006) 27: 4975-4983.
25. Von Storp B, Engel A, Boeker A, Ploeger M and Langer K. Albumin nanoparticles with predictable size by desolvation procedure. J. Microencapsulation (2012) 29: 138-146.
26. Rahimnejad M, Najafpour G and Bakeri G. Investigation and modeling effective parameters influencing the size of BSA protein nanoparticles as colloidal carrier. Colloids Surf. A (2012) 412: 96-100.